Tag:
Prism Pharmaceuticals
Latest Headlines
Latest Headlines
Baxter nabs Prism's arrythmia drug in $338M buyout
Just months after gaining an FDA approval for ready-to-use IV formulations of its anti-arrhythmic agent Nexterone, Prism Pharmaceuticals has sealed a $338 million buyout deal with Baxter
